This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers
Urol Oncol. 2021 Jun;39(6) :312-315
PMID: 32402770 URL: https://www.ncbi.nlm.nih.gov/pubmed/32402770
AbstractClinical interest in poly(ADP-ribose) polymerase 1 (PARP-1) has increased over the past decade with the recognition of its roles in transcription regulation, DNA repair, epigenetic bookmarking, and chromatin restructuring. A number of PARP-1 inhibitors demonstrating clinical efficacy against tumors of various origins have emerged in recent years. These inhibitors have been essentially designed as nicotinamide adenine dinucleotide (NAD(+)) mimetics. However, because NAD(+) is utilized by many enzymes other than PARP-1, NAD(+) competitors tend to produce certain off-target effects. To overcome the limitation of NAD-like PARP-1 inhibitors, we have developed a new class of PARP-1 inhibitors that specifically targets the histone-dependent route of PARP-1 activation, a mechanism of activation that is unique to PARP-1. Novel histone-dependent inhibitors are highly specific for PARP-1 and demonstrate promising in vitro and in vivo efficacy against prostate and renal tumors. Our findings suggest that novel PARP-1 inhibitors have strong therapeutic potential for the treatment of urological tumors.
Notes1873-2496 Makhov, Peter Uzzo, Robert G Tulin, Alexei V Kolenko, Vladimir M Journal Article Review United States Urol Oncol. 2020 May 8. pii: S1078-1439(20)30145-9. doi: 10.1016/j.urolonc.2020.04.004.